Lactobacillus brevis NTM003 for Dual Hyperuricemia and Fatty Liver Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperuricemia and fatty liver often require long-term lifestyle changes and medication, with a need for a safe and effective method that can concurrently address both conditions, as existing lactic acid bacteria are specific to either serum uric acid reduction or fatty liver prevention.
Innovation Solution
Development of Lactobacillus brevis NTM003 strain, which is orally administered to suppress serum uric acid levels and reduce liver lipid content, offering a dual-function solution for hyperuricemia and fatty liver management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If separate lactic acid bacteria are used for serum uric acid reduction or fatty liver prevention, then each specific function is achieved, but a single bacterium that concurrently addresses both conditions has not been available
Solution Approach 1:
The patent applies universality by developing Lactobacillus brevis NTM003 strain that performs multiple functions simultaneously - it reduces serum uric acid levels and prevents fatty liver accumulation. This single multi-functional bacterium replaces the need for separate bacteria for each condition, directly resolving the technical contradiction between versatility and complexity.
2Reliability
If lifestyle changes are implemented for long-term control of hyperuricemia and fatty liver, then health improvement is achieved, but compliance and sustained control are difficult
Solution Approach 1:
The patent applies self-service by utilizing the natural metabolic activities of Lactobacillus brevis NTM003 strain to perform the therapeutic functions. The bacterium itself carries out the work of reducing uric acid and preventing fatty liver through its inherent enzymatic capabilities, eliminating the need for complex lifestyle interventions while maintaining reliable treatment effectiveness.
3Reliability
If medication therapy is used for hyperuricemia and fatty liver, then blood uric acid level is controlled, but side effects and medical intervention requirements increase
Solution Approach 1:
The patent applies the intermediary principle by introducing Lactobacillus brevis NTM003 strain as a biological mediator between the host's metabolic system and the harmful substances (uric acid and liver fat). The bacterium safely processes and reduces these substances through its metabolic pathways, achieving reliable blood uric acid control without the harmful side effects associated with conventional medication therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Lactobacillus brevis NTM003 strain effectively suppresses serum uric acid levels and reduces liver lipid content, providing a novel approach for the prophylaxis and treatment of hyperuricemia and fatty liver, and can be used in pharmaceutical and food products to support lifestyle-related disease management.
Implementation Method 1
a method of decreasing absorption of purine body into the body by decomposing the purine body in the intestine by oral ingestion of microorganism such as lactic acid bacterium and yeast that decompose purine body
Implementation Method 2
Lactobacillus brevis NTM003 strain effectively suppresses serum uric acid levels
Implementation Method 3
reduces liver lipid content
Data Source
AI summary
The present invention provides a lactobacillus that improves hyperuricemia, fatty liver and a lifestyle-related disease, and a composition containing the lactobacillus.